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Erythropoietin (EPO) is a glycoprotein 
that is critical for the regulation of red 
blood cell production. During embryonic 
development, Epo is mainly expressed in 
the fetal liver. However, as hematopoi-
esis switches sites from the fetal liver to 
the bone marrow, peritublular interstitial 
cells of the kidney support EPO produc-
tion. Epo expression is tightly regulated by 
spatial, temporal and environmental cues.1 
Clinically, the regulation of EPO is criti-
cal as overproduction of EPO results in the 
development of polycythemia and insuffi-
cient EPO production results in anemia. 
Over 3 million patients suffer from ane-
mia as a result of insufficient renal EPO 
production. Currently, the use of recom-
binant Epo is the conventional treatment 
for anemia associated with chronic kidney 
disease. While this has revolutionized 
and transformed the lives of millions of 
patients, the use of recombinant Epo is 
costly, requires supervised administration 
and can have immunogenic side effects.2 
Therefore, the identification of endog-
enous sources of EPO outside of the kid-
ney that may be activated in adults for the 
treatment of renal anemia is of great thera-
peutic value.
EPO expression is regulated by the 
hypoxia-inducible factor (HIF) family 
of transcription factors.1 Both HIF-1α 
and HIF-2α activate a cascade of genes 
including EPO in response to low tissue 
oxygenation or hypoxia.3 While HIF-1α 
and HIF-2α have overlapping and distinct 
tissue-specific expression patterns and tar-
get genes, stabilization of both proteins, in 
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the presence of oxygen is dependent upon 
hydroxylation on specific proline residues 
by prolyl hydroxylase (PHD) enzymes. 
Hydroxylation of HIFs allows for the 
binding of the von Hippel-Lindau (VHL) 
protein which targets these proteins for 
proteosomal degradation.4 As hydroxyl-
ation of HIF is a key regulatory process in 
HIF-mediated gene transcription, the dis-
covery and development of small-molecule 
PHD inhibitors (PHI) that can mimic the 
hypoxic response provides exciting possi-
bilities for the treatment of oxygen-depri-
vation related disorders such as anemia.
In Volume 149, Issue 1 of Cell, Rankin 
et al. discovered a previously unidentified 
source of endogenous Epo capable of stim-
ulating erythropoiesis (Fig. 1). In their 
studies, a Cre-loxP approach was used to 
inactivate VHL and, thus, constitutively 
activate HIF signaling, specifically in cells 
of the osteoblastic lineage. Augmented 
HIF activity in osteoblasts resulted in 
enhanced erythropoiesis marked by the 
development of severe polycythemia by 8 
weeks of age in 100% of mutant mice. The 
development of polycythemia occurred in 
an EPO-dependent manner and was asso-
ciated with an increase in EPO expression 
in bone and decreased EPO expression in 
the kidney. Elevated bone EPO expression 
occurred in a HIF-2α-dependent manner, 
demonstrating that HIF-2α expression 
in osteoblasts drives EPO expression in 
bone. In the endogenous setting, Rankin 
et al. found that bone and primary osteo-
blasts cultures from neonatal mice also 
expressed Epo in a HIF-2α dependent 
manner. Studies investigating the endog-
enous role of EPO in bone are eagerly 
awaited, as homeostatic erythropoiesis 
was maintained in HIF-2α-deficient mice.
The discovery that osteoblasts have 
the capacity to regulate Epo expression in 
bone and, in turn, to directly modulate 
erythropoiesis raises the exciting possibil-
ity that manipulation of HIF signaling in 
osteoblasts may prove beneficial for the 
treatment of anemia. In support of this 
hypothesis, Rankin et al. demonstrated 
that mice with constitutive HIF activ-
ity in osteoblasts were indeed protected 
against hemolytic anemia. To examine 
the potential clinical implications of their 
findings, Rankin and colleges generated a 
second murine model in which all three 
PHD isoforms were specifically inacti-
vated in cells of the osteblastic lineage. 
These mice also developed polycythemia 
associated with upregulation of Epo in 
bone tissue. Furthermore, exposure of the 
bone marrow microenvironment to pan 
PHD inhibitors was sufficient to induce 
Epo expression in the bone.5 These find-
ings highlight the therapeutic potential of 
targeting the PHD/VHL/HIF signaling 
pathway in osteoblasts for the treatment 
of anemia.
The genetic and pharmacological 
data from these studies have important 
clinical implications for the treatment 
of anemia in the context of renal insuffi-
ciency. Pharmacological manipulation of 
the HIF signaling pathway through the 
inhibition of prolyl hydroxylaes enzymes 
represents a novel treatment option, as © 2012 Landes Bioscience.
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the clinical benefits seen in these patients. 
As the bone marrow serves as the major 
site of post-natal erythropoiesis, the abil-
ity to directly modulate erythropoiesis 
through osteoblastic expression of EPO 
indicates that PHD inhibition within 
bone tissue could be an effective and 
efficient therapeutic modality for those 
suffering from renal anemia. In light of 
these recent findings, it will be important 
to evaluate the relative contribution of 
hepatic vs. osteoblastic Epo production 
in the context of renal insufficiency for 
those patients receiving treatment with 
PHIs.
these small-molecule inhibitors are less 
costly and more easily administered than 
recombinant EPO. Several classes of PHD 
inhibitors (PHI) are currently in clinical 
trials for the treatment of renal anemia.6 
However, the mechanisms by which PHIs 
protect against renal anemia are not fully 
understood. It is postulated in patients 
suffering from renal failure, PHIs activate 
HIF-2α within the liver leading to the 
reactivation of hepatic Epo production.7,8 
The studies performed by Rankin et al. 
identify a previously unknown source of 
Epo, raising an intriguing hypothesis that 
osteoblastic Epo could also contribute to 
Figure 1. EPo production for the regulation of erythropoiesis occurs in the fetal liver and adult 
kidney. rankin and Wu et al. demonstrate that manipulation of the PHd/VHL/HiF signaling path-
way in osteoblasts elevates the erythroid lineage in the local hematopoietic environment and 
protects from anemia through modulation of EPo expression in bone. these findings implicate 
osteoblasts in bone as a novel source of endogenous EPo to stimulate erythropoiesis. the image 
depicts the regulation of erythropoiesis by an osteoblast with augmented HiF activity. rankin 
and colleagues demonstrate that osteoblasts (shown attached to the bone surface) secrete EPo 
(green), which stimulates erythroid progenitor (purple) proliferation and differentiation in the 
bone marrow microenvironment. artwork by Butch Colyear.
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